Vaishali Pharma Limited — Capital/Financing Update 2021

Jan 4, 2021

==> picture [53 x 44] intentionally omitted <==

==> picture [70 x 36] intentionally omitted <==

==> picture [37 x 37] intentionally omitted <==

==> picture [132 x 11] intentionally omitted <==

Vaishali Pharma Limited CIN: L52310MH2008PLC181632

==> picture [271 x 43] intentionally omitted <==

PRESS RELEASE

THE COMPANY HAS ACHIEVED MAJOR MILESTONE BY ENTERING INTO IN-LICENCING AGREEMENT FOR THE U.S.A MARKET

Mumbai, January 04, 2021 : Vaishali Pharma Limited (NSE: Vaishali), A Mumbai based Organisation, engaged in catering Pharmaceutical Product across PAN India & Internationals. A company abided by the norms of extending uncompromised quality products, has raised the standards of Pharmaceutical & Healthcare Industry time and again. Through unwavering dedication, consistent efforts and endless Innovation, Vaishali Pharma has set new benchmarks Year On Year.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the Pharmaceutical Industry for the Healthcare Products to Domestic & International Market.

The Indian Pharmaceutical Industry supplies major portions of global demand for Healthcare products and accounts for 20% of the global exports in generics. The Indian healthcare sector is expected to record a threefold rise, at a CAGR of 22% during 2016-2022 to reach US$ 372 billion in 2022 from US$ 110 billion in 2016, whereas the U.S. Healthcare Market generated $61.01 billion in 2017, and is projected to reach $149.17 billion by 2025, growing at a CAGR of 11.7% from 2018 to 2025. Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the export of Pharmaceutical products across the globe.

Healthcare Industry in India has been one of the Country’s largest economic sector, with regards to both Employment & Revenue . Currently the company is into the In Licensing Agreement with U.S. A. Healthcare Market for the Healthcare Products . Our Exposure to International Market in catering Quality Products, has fetch a new set of business for us from U.S.A. Healthcare Market. Initially 5 Products have been finalized to be sourced for the U.S.A. Healthcare Market as per the In Licensing Agreement for the Healthcare Products .

The Company is striving hard to double the product range in various countries in coming years and working in that direction consistently.

ABOUT VAISHALI PHARMA LIMITED:

Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The company has over 150+ formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The company has

Vaishali Pharma Limited CIN: L52310MH2008PLC181632

==> picture [271 x 43] intentionally omitted <==

built a robust pipeline of around 250 Dossiers. The Company’s synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, wellqualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

At Vaishali Pharma Limited, we are working tirelessly to make available health improving pharmaceutical products affordable and accessible to all. Looking beyond this immediate term, the upcoming half year shall present more good opportunities for the Company and we shall continue to perform better than the previous half year.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects. One can count upon us for quality pharmaceutical and healthcare products.

For more details please visit: www.vaishalipharma.com For any Investor Relations query, please contact:

Mr. Akshay JharkhandiCompany SecretaryEmail: cs@vaishalipharma.com	Mr. Ratnesh SinghChief Financial OfficerEmail: investor@vaishalipharma.com

Note: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.